Diagnostic utility of serum anti-Mullerian hormone levels in south Indian women with polycystic ovarian syndrome
Keywords:Anti-müllerian hormone, Polycystic ovarian syndrome, Rotterdam criteria, antral follicular count, ovarian volume
Introduction and Aim: Polycystic ovarian syndrome (PCOS) is a prevalent endocrinopathy among women of reproductive age group, conventionally diagnosed using multiple clinical and biochemical tests. We aimed to evaluate the diagnostic utility of serum anti-Müllerian hormone (AMH) levels in PCOS.
Materials and Methods: The case control study involved 60 women of 18-40 years age, further grouped using Rotterdam criteria as cases with PCOS (n = 30) and controls without PCOS (n = 30). Study variables were compared between the groups using independent t-test. Correlation analyses were performed to predict the relationship of AMH with other PCOS determinants. Simple logistic regression and ROC analyses were used to determine the diagnostic utility of AMH.
Results: PCOS cases had increased levels of serum LH, testosterone, AMH, BMI, total antral follicular count (AFC), ovarian volume (OV) (p < 0.05*) than controls. Of all, serum AMH had the strongest association with PCOS (OR > 1, p < 0.05*) and showed considerable positive correlations with LH:FSH ratio, testosterone, AFC (r = 0.7768, p < 0.05*), OV (r = 0.7981, p < 0.05*). ROC analysis of AMH was significant (AUC = 0.966, p < 0.05*) with high sensitivity, specificity for cut points between 5.595 ng/mL and 5.90 ng/mL.
Conclusion: Elevated serum AMH levels were strongly associated with PCOS and correlated with its routine clinical determinants. Serum AMH estimation with cut-off between 5.595 ng/mL to 5.90 ng/mL, is proposed as a useful index for PCOS diagnosis.
Hegde P, Shetty PK, Shetty SS, Manjeera L, Shetty DP. A study on changes in hormonal disruption in polycystic ovary syndrome with advancing age and body mass index. Biomedicine. 2022 Jul 3;42(3):461-8.
Auda SA, Gatea EA, Radhi ZA. Evaluation of thyroid autoimmunity markers in polycystic ovarian syndrome in women. Biomedicine. 2023 Jul 1;43(3):893-6.
Wu, S., Divall, S., Nwaopara, A., Radovick, S., Wondisford, F., Ko, C., et al., Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014;63:1270-1282.
Lavanya K, Palaniappan N, Vinodhini VM, Kumar M, Silambanan S. Association of prolactin and insulin with obesity in women with polycystic ovarian syndrome. Biomedicine. 2022 Dec 31;42(6):1166-71.
Dev D, Dutta P. A novel approach to treat polycystic ovarian syndrome (PCOS) patients. Biomedicine. 2022 Sep 12;42(4):841-3.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., Azziz, R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6-15.
Moolhuijsen, L.M.E., Visser, J.A. Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105:3361-3373.
Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151-1157.
Cook, C.L., Siow, Y., Brenner, A.G., Fallat, M.E. Relationship between serum Müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141-146.
Parahuleva, N., Pehlivanov, B., Orbecova, M., Deneva, T., Uchikova, E. Serum levels of anti-Mullerian hormone in women with polycystic ovary syndrome and healthy women of reproductive age. Akush Ginekol (Sofiia). 2013;52:16-23.
World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. 2000;1:17-20.
Lim, S.S., Davies, M.J., Norman, R.J., Moran, L.J. Overweight, obesity, and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618-637.
Morshed, M., Banu, H., Akhtar, N., Sultana, T., Begum, A., Zamilla, M., et al., Luteinizing hormone to follicle-stimulating hormone ratio significantly correlates with androgen level and manifestations are more frequent with hyperandrogenemia in women with polycystic ovary syndrome. J Endocrinol Metab. 2021;11:14-21.
Laven, J. S., Mulders, A.G., Visser, J.A., Themmen, A.P., DeJong, F.H., Fauser, B.C. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318-323.
Abbara, A., Eng, P.C., Phylactou, M., Clarke, S.A., Hunjan, T., Roberts, R., et al., Anti-Mullerian hormone (AMH) in the diagnosis of menstrual disturbance due to polycystic ovarian syndrome. Front Endocrinol (Lausanne). 2019;10:1-9.
Pigny, P., Merlen, E., Robert, Y., Cortet-Rudelli, C., Decanter, C., Jonard, S., et al., Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957-5962.
Mahajan, N., Kaur, J. Establishing an anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated anti-Müllerian hormone assay. J Hum Reprod Sci. 2019;12:104-113.
Ahmed, N., Batarfi, A.A., Bajouh, O.S., Bakhashab, S. Serum anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome in association with clinical symptoms. Diagnostics (Basel). 2019;9:1-6.
Lujan, M.E., Chizen, D.R., Pierson, R.A. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008;30:671-679.
Amer, S.A., Li, T.C., Bygrave, C., Sprigg, A., Saravelos, H., Cooke, I.D. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod. 2002;17:1616-1622.
Hehenkamp, W.J., Looman, C.W., Themmen, A.P., DeJong, F.H., TeVelde, E.R., Broekmans, F.J. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91:4057-4063.
Catteau-Jonard, S., Bancquart, J., Poncelet, E., Lefebvre-Maunoury, C., Robin, G., Dewailly, D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol. 2012;40:223-229.
Saxena, U., Ramani, M., Singh, P. Role of AMH as a diagnostic tool for polycystic ovarian syndrome. J Obstet Gynaecol India. 2018;68:117-122.
How to Cite
Copyright (c) 2023 Biomedicine
This work is licensed under a Creative Commons Attribution 4.0 International License.